Form 4: Protagonist Therapeutics CEO Sells 35,000 Shares Under 10b5-1 Plan
SEC Form 4
Dinesh V. Patel, CEO of Protagonist Therapeutics, sold 35,000 shares of common stock at an average price of $35.19 per share on June 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 7, 2024, Dinesh V. Patel, the President and CEO of Protagonist Therapeutics, sold 35,000 shares of the company's common stock.
- The sale was executed at a weighted average price of $35.19 per share.
- The shares were sold in multiple transactions with prices ranging from $35.00 to $35.53.
- This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 20, 2023.
- Following the transaction, Patel directly owns 515,415 shares of Protagonist Therapeutics.
- This amount includes 825 shares acquired through the company's 2016 Employee Stock Purchase Plan on March 9, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction was executed under a pre-arranged 10b5-1 trading plan, indicating it was likely part of a planned diversification strategy rather than a reaction to current company performance.
Industry Context
Sales by company executives are a normal part of corporate governance. Investors often monitor these sales to understand management's perspective on the company's valuation and future prospects. Sales under 10b5-1 plans are less likely to be indicative of management sentiment, as these plans are pre-arranged.
Comparison to Industry Standards
- Executive stock sales are common across the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen regularly see insider transactions.
- The size and frequency of these transactions vary based on individual financial planning and company performance.
- Rule 10b5-1 plans are a standard tool used by executives to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sale mitigates this impact.
- Employees may be interested in insider transactions as an indicator of company health, but the 10b5-1 plan context should reassure them.
Key Dates
| Date | Description |
|---|---|
| 2023-03-20 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 2024-03-09 | Date the Reporting Person acquired 825 shares under the Issuer's 2016 Employee Stock Purchase Plan |
| 2024-06-07 | Date of the transaction (sale of shares) |
| 2024-06-11 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.